Cara Therapeutics Inc CARA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.70
- Day Range
- $0.68–0.73
- 52-Week Range
- $0.51–4.67
- Bid/Ask
- $0.68 / $0.68
- Market Cap
- $37.41 Mil
- Volume/Avg
- 169,234 / 643,275
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.89
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 55
- Website
- https://www.caratherapeutics.com
Comparables
Valuation
|
Metric
|
CARA
|
MORF
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.70 | 1.98 | 12.65 |
Price/Sales | 1.89 | 2,253.05 | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
CARA
MORF
CBAY
Financial Strength
|
Metric
|
CARA
|
MORF
|
CBAY
|
|---|---|---|---|
Quick Ratio | 4.09 | 28.43 | 10.70 |
Current Ratio | 4.54 | 28.94 | 10.96 |
Interest Coverage | −195.21 | — | −5.27 |
Quick Ratio
CARA
MORF
CBAY
Profitability
|
Metric
|
CARA
|
MORF
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −73.68% | −18.85% | −30.06% |
Return on Equity (Normalized) | −95.77% | −19.43% | −51.97% |
Return on Invested Capital (Normalized) | −92.23% | −23.26% | −30.87% |
Return on Assets
CARA
MORF
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sfdlmnkv | Kjv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fwrvwwyzv | Kcwyll | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kklfjgkcy | Tyxdgt | $97.8 Bil | |
MRNA
| Moderna Inc | Zhxhrtbw | Ygbpp | $38.8 Bil | |
ARGX
| argenx SE ADR | Rjwcsjypp | Mdzgf | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Vbtdntr | Fhtx | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jmbkqkcj | Jqngpsg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dzmmbjjf | Zpwkjx | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vwkzjwkg | Dpbchzc | $12.5 Bil | |
INCY
| Incyte Corp | Dgrfkflrv | Qtqwx | $11.5 Bil |